Market Research Blog – Page 533 – New Product Development

Brilliant Black BN Colors Market Exploring the Growing Demand for Food-Grade Coloring Solutions

The global Brilliant Black BN Colors market size, valued at USD 5.11 million in 2022, is projected to reach USD 6.7 million by 2032, expanding at a steady CAGR of 2.7% during the forecast period from 2022 to 2032, according to the latest analysis by Future Market Insights (FMI). By volume, the market reported a consumption of 1200 metric tons globally in 2021.

Brilliant Black BN, also known by various names including Food Black 1 and Naphthol Black, is a synthetic black diazo dye that is water-soluble and widely used in the food and beverage industry. Its affordability and effectiveness in imparting intense, uniform color have made it a popular choice among manufacturers.

Key Drivers of Market Growth

Rising Demand for Confectionery and Dessert Products: The increasing consumer preference for visually appealing confectionery and dessert items has significantly driven the demand for Brilliant Black BN colors. The dye is extensively used in products such as cakes, pastries, cookies, biscuits, and savory snacks. The trend of ready-to-eat food products, fueled by rapid urbanization and changing lifestyles, further bolsters market growth.
Influence of Social Media: Social media platforms like Instagram and TikTok play a pivotal role in shaping food trends, with visually striking dishes gaining popularity. Brilliant Black BN colors enable food manufacturers to create unique and appealing products that cater to these trends, enhancing their market presence.
Cost-Effectiveness and Availability: Brilliant Black BN colors are more affordable and available in larger quantities compared to natural food colorants. This cost-effectiveness makes them a preferred choice in emerging and underdeveloped economies where awareness of organic food colors is still growing.

Challenges and Restraints

Stringent Regulations: Regulatory restrictions in countries like the USA, Switzerland, and Japan, where Brilliant Black BN colors are banned, pose significant challenges to market expansion. Despite its approval by the European Union, varying regulations across regions affect the market’s overall growth.
Health Concerns: Potential health risks associated with synthetic food colors, including Brilliant Black BN, lead to consumer hesitancy. The growing preference for natural ingredients further hampers the market’s growth prospects.

Regional Insights

The Asia-Pacific region, with a consumption of approximately 370 metric tons in 2021, holds a significant share of the global market. China, in particular, is a major market due to its large food processing industry. Key manufacturers like Hangzhou Dayangchem Co. Ltd. and San-Ei Gen F.F.I., Inc. have a strong presence in this region.

Europe remains a substantial market with sales exceeding 250 metric tons in 2021. The region’s stringent regulations and consumer awareness drive the demand for high-quality food colorants.

Emerging food processing industries in these regions continue to create promising growth opportunities for the Brilliant Black BN colors market. Brazil, for instance, recorded sales of USD 570,000 in 2021.

Market Opportunities and Competitive Landscape

Innovation and Product Development: Companies like Sensient Food Colors are investing in R&D to enhance the water solubility and heat stability of Brilliant Black BN colors, making them more attractive to end-users. Vinayak Ingredients Pvt Ltd. recently launched a new batch of the dye for use in decorations and confectionery coatings.
Strategic Partnerships and Expansions: Large manufacturers, including Sigma-Aldrich International GmbH, are acquiring innovative regional units and expanding their applications to sectors like pet foods and edible cosmetics.

Brilliant Black BN Colors Market By Category

On the basis of form:

Solid
Powder
Granulated

By Application:

Beverage
Bakery, Snacks, and Cereals
Candy/ Confectionery
Dairy
Fruit Preparations/ Fillings
Meat, Poultry, Fish, and Eggs
Potatoes, Pasta, and Rice
Sauces, Soups, and Dressings
Seasonings
Pet Food

By Region:

Global
North America
Latin America
Europe, the Middle East and Africa, and India
Asia Pacific

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Botanical Ingredients Market Unlocking the Potential of Natural Products in Health and Wellness

The botanical ingredients market is slated to progress at a CAGR of 7.3%. This will elevate the market size from US$ 185.91 billion to US$ 374.84 billion from 2024 to 2034. The growing healthcare, cosmetic, and food and beverage markets leverage the demand for botanical ingredients.

Changing consumer lifestyles levitate the demand for eco-friendly products. In addition, consumers demand healthy products, driving the production of botanical ingredients. Hence, this boosts the natural food ingredient market size. The strengthening and diversification of distribution networks will increase the demand for botanical ingredients. Multiple choices can become available to customers, enhancing the natural food ingredient market growth prospects.

Technological infrastructure is growing, assisting leading botanical ingredient manufacturers in producing innovative and sustainable botanical ingredients. It will generate more options for consumers, driving the plant-based ingredient market. The growing concern for sustainability will be another critical mainstream driver for the botanical ingredient market.

Key Takeaways from the Market Study

• From 2019 to 2023, the market for botanical ingredients advanced at a 6% CAGR.

• The Indian botanical ingredient market growth will be the fastest, which projects the highest CAGR of 7.1%.

• The United States of America is the largest market by size, estimating the advancement at a CAGR of 4.4%.

• Liquid plant extract is the largest segment based on form, securing 26.5% of the market space.

“Synthetic products can be perfect substitutes for organic products, which can be a serious restraint for the botanical ingredient market,” says Nandini Roy Choudhury, Client Partner at Future Market Insights.

Competitive Landscape of the Botanical Ingredient Market

Leading botanical ingredient manufacturers occupy a large market space, hindering new entrants’ entry path. However, new entrants might enhance their market presence through effective brand positioning.

Key marketers use product launches, partnerships, collaborations, acquisitions, and alliances to maintain their competitive advantage in the market. The following key developments have changed the competitive landscape:-

• In August 2022, Archer Daniels Midland Company partnered with New Culture. The strategic move intended to uplift dairy production. Also, the organization focused on innovating products and commercializing them.

• In May 2023, International Flavors & Fragrances Inc. initiated and completed a divestiture of its Savory Solutions business unit to PAI Partners. This helped the organization eliminate its liabilities and assets, leveraging free cash flow.

Key Companies Profiled

Archer Daniels Midland Company
International Flavors& Fragrances Inc.
Koninklijke DSM NV
Martin Bauer Group
Bell Flavors & Fragrances
Givaudan
Döhler GmbH
Koninklijke Euroma BV
Botanical Ingredients Ltd.
Nutrasorb LLC.

Botanical Ingredients Market by Category

By Ingredient:

Herbs & Spices
Vegetables & Fruits
Flowers
Leaves
Seeds & Nuts
Barks & berries
Bulbs & Roots
Others

By Form:

Dried Plants
Liquid Plant Extract
Oleoresins
Others

By End User:

Commercial Chains
Residential Uses

By Application:

Food & Beverages
Nutraceuticals & Dietary Supplements
Pet Care Industry
Pharmaceuticals
Cosmetics and Personal Care
Commercial HouseholdsOthers

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Aqua Feed Additives Market Navigating Growth Trends and Innovations for Sustainable Aquaculture

The aqua feed additives market is expected to reach a valuation of USD 1.8 billion by the year 2024, accelerating with a CAGR of 5.5% by 2024 to 2034.

In recent years, the aqua feed additives sector has witnessed dynamic growth driven by advancements in aquaculture practices and evolving consumer demands for sustainable and nutritionally enhanced seafood products. Key trends shaping the market indicates a growing emphasis on specialty applications of aqua feed additives, particularly in enhancing the health, growth, and overall productivity of aquatic species.

Some of the key factors driving the rise of the aqua feed additives market share are growing worries about receiving the right vitamin and mineral additives for aquatic animals.

As individuals become more aware of premixes, the demand for aqua feed additives has increased. As a result of the increased demand for mineral-rich aqua feed additives, companies are seeing an increase in sales of aqua feed additives.

Increased understanding of bioavailability in these compounds is another important driver of the aqua feed additives market size. As a result, aqua feed additives manufacturers are increasing production of direct mineral supplements to suit end-user demand.

The trade of fish and aquaculture products plays a significant role in expanding fish consumption and building a global market for aqua feed additives by connecting various worldwide suppliers and manufacturers.

As adaptive pathogens can be infected by a variety of stress factors, including poor nutritional status, sales of aqua feed additive are on the rise. Antibiotics are also used to treat diseases such as red pest disease, which drives up demand for aquaf eed additives around the world.

The growing demand for high-protein diets is presenting excellent growth opportunities for the aqua feed additives market, particularly in emerging economies like Brazil, India, and China, where per capita income is rapidly rising, resulting in increased sales of aqua feed additives.

Key Takeaways from the Aqua feed Additives Market Study:

The Germany is estimated to account for more than 4.2% of the North American market in 2024, due to the rising in seafood consumption.
The aqua feed additives market in the China is predicted to grow at a CAGR of 5.7 percent from 2024 to 2034.
Due to a considerable availability of raw materials and the presence of large-scale companies, Egypt has a strong demand for aqua feed additives.
According to FMI, the aqua feed additives market in Japan is predicted to grow at a CAGR of 3.8 percent through 2034.

“Key market players are investing much in R&D in order to introduce new products and obtain a competitive advantage. Companies are also pursuing tactics such as collaboration, acquisitions, mergers, and partnerships in order to extend their client base and increase revenues.”- Lead Analyst at FMI.

Competition Landscape of Aqua feed Additives Market

Key players operating in the global aqua feed additives market are focusing on reaching a large consumer base by implementing various strategies such as product innovations, marketing & promotional activity, strengthening distribution channels, and adopting sustainable production.

Some of the leading companies in aqua feed additives market are Cargill, Inc., NK Ingredients Pte. Ltd., Beneo GmbH, Dibaq A.S., Nutreco N.V., Evonik Industries, Biomar A/S, Growel Feeds, Coppens International B.V., Aker Biomarine and others.

Recent Developments in Aqua feed Additives Market:

ADM purchased Neovia (formerly known as InVivo NSA) (France) in January 2019 for USD 1.82 billion (Euro 1.54 billion). This acquisition would give ADM a strong foundation on which to build future expansion.
In November 2018, Cargill invested USD 70 million in Thailand to provide new technologies to the country’s aquaculture and poultry industries.
In June 2017, Nutreco completed the acquisition of Hi-Pro Feeds LP (Canada). The acquired company’s global brand, Trouw Nutrition, would be used to market the acquired company.

Aqua Feed Additives Market by Category

By Additives Type, Aqua Feed Additives Market is Segmented as:

Amino Acids
Vitamins
Minerals
Antibiotics
Acidifiers
Binders
Antioxidants
Prebiotics
Palatants
Others

By Species Type, Aqua Feed Additives Market is Segmented as:

Crustaceans
Catfish
Salmonids
Carp
Tilapia
Mollusks
Mullet

By Ingredient, Aqua Feed Additives Market is Segmented as:

Corn
Soybean
Fish Oil
Peas
Sunflower Seed
Others

By Region, Aqua Feed Additives Market is Segmented as:

North America
Latin America
Europe
Asia Pacific
MEA

About Future Market Insights (FMI)

Contact Us:

Revolutionizing Neurological Care: Global Gene Therapy in CNS Disorder Market to Surge to USD 113.04 Billion by 2033

The global gene therapy in CNS disorder market is poised for unprecedented growth, with market valuation anticipated to skyrocket from USD 8.2 billion in 2023 to USD 113.04 billion by 2033, registering a robust compound annual growth rate (CAGR) of 30% during the forecast period. This remarkable growth trajectory reflects increasing advancements and demand for cutting-edge therapeutic interventions for neurological conditions.

Historical Market Insights:

In the historical period from 2018 to 2022, the market for gene therapy in CNS disorders demonstrated steady progress, achieving a CAGR of 19%. This growth was fueled by heightened R&D investments, innovative technological applications, and a burgeoning awareness of the transformative potential of gene therapy in treating debilitating neurological conditions.

Driving Forces Behind the Growth:

The exponential rise in the gene therapy market can be attributed to:

Innovative Advancements: Emerging technologies, such as CRISPR and viral vector delivery systems, are revolutionizing therapeutic efficacy and precision.
Rising Prevalence of CNS Disorders: Conditions like Alzheimer’s, Parkinson’s, Huntington’s disease, and ALS drive demand for novel treatment options.
Increased Investment in R&D: Pharmaceutical giants and biotechnological firms are channeling resources into gene therapy solutions, paving the way for breakthrough developments.

Forecast for the Future:

Over the next decade, the market is expected to witness widespread adoption as regulatory frameworks become more streamlined and access to advanced therapies broadens. Furthermore, collaborations between academic institutions, biotech companies, and healthcare providers are likely to accelerate innovation and bring transformative treatments closer to patients.

Industry Implications:

The projected growth underscores the transformative impact gene therapy is expected to have on the management and treatment of CNS disorders. It highlights the shift toward precision medicine and a future where chronic and life-altering neurological conditions could be mitigated effectively.

As the global healthcare landscape embraces this transformative wave, stakeholders across the pharmaceutical, healthcare, and biotech industries are presented with unparalleled opportunities to shape the future of neurological care.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Key Takeaways from the Market Study:

From 2018 to 2022, the Gene Therapy in CNS Disorder market grew at a CAGR of 19%.
The global Gene Therapy in CNS Disorder market is expected to grow with a 30% CAGR during 2023 to 2033.
As of 2033, the Gene Therapy in CNS Disorder Market is expected to reach USD 113.04 Billion.
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess 40% market share for the Gene Therapy in CNS Disorder market.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst

Market Competition:

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.

In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.

Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey

Indication:

Alzheimer’s Disease
Huntington’s Disease
Parkinson’s Disease
Batten Disease

Type:

Ex Vivo
In Vivo

End User:

Hospitals
Speciality Clinics

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Cocaine Intoxication Treatment Market to Reach USD 17.91 Million by 2033, Driven by Rising Awareness and Advancements in Treatment Options | FMI

The global cocaine intoxication treatment market is poised for significant growth, with market value expected to increase from USD 10 Million in 2023 to an impressive USD 17.91 Million by 2033, registering a robust CAGR of 6% during the forecast period (2023-2033). This is a marked improvement from the 4% CAGR recorded during the historical period of 2018-2022, signaling a shift in the landscape of treatment options and healthcare interventions for cocaine intoxication.

Key Drivers of Market Growth:

Rising Prevalence of Cocaine Use

With increasing awareness of substance abuse disorders globally, the need for effective treatments to combat cocaine intoxication has become critical. Healthcare systems are increasingly focused on addressing this issue through enhanced treatment protocols.

Advancements in Pharmaceutical Research

Innovation in pharmacological treatments and supportive therapies is anticipated to drive demand. New drug formulations and therapeutic strategies are gaining traction, contributing to market expansion.

Government and Non-Governmental Efforts

Proactive initiatives by government bodies and non-profit organizations are fostering the adoption of treatments, facilitating early interventions and access to care.

Regional Insights:

North America continues to dominate the market, owing to advanced healthcare infrastructure, high awareness levels, and government support.
Europe follows closely, with increasing investments in substance abuse treatment programs.
Emerging markets in Asia-Pacific and Latin America are witnessing growing demand, driven by rising prevalence and improving healthcare accessibility.

The Cocaine Intoxication Treatment Market features a mix of established players and emerging innovators. Companies are focusing on R&D, collaborations, and strategic partnerships to strengthen their market presence.

Future Outlook:

As healthcare systems globally recognize the growing challenge of substance abuse, the Cocaine Intoxication Treatment Market is expected to witness sustained growth. Stakeholders in the pharmaceutical and healthcare sectors are well-positioned to capitalize on this opportunity, delivering effective solutions to address this pressing issue.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Key Takeaways from the Market Study:

The Cocaine Intoxication Treatment market expanded at a CAGR of 4% from 2018 to 2022.
From 2023 to 2033, the market for treating cocaine intoxication is projected to expand at a 6% CAGR.
The market for treating cocaine intoxication is anticipated to reach USD17.91 million by 2033.
Hospital pharmacies hold the biggest market share, per the FMI research.
For the Cocaine Intoxication Treatment market, North America is anticipated to have a 40% market share. With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cocaine Intoxication Treatment.” says an FMI analyst

Market Competition:

Key players in the market include pharmaceutical companies such as Tonix Pharmaceutical, GlaxoSmithKline Plc., Bristol Myers Squibb Company, Pfizer Inc., Novartis AG, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., and Advanz Pharmaceuticals, along with healthcare providers and technology companies among other global players.

Tonix Pharmaceuticals Holding Corp. was awarded a grant in August 2022 by the National Institute on Drug Abuse to aid the advancement of TNX-1300, a recombinant enzyme that targets the treatment of cocaine intoxication. Cocaine abuse can have harmful impacts on multiple bodily systems, primarily the cardiovascular system, and can lead to fatal consequences. TNX-1300 has been demonstrated to counteract the physiological consequences of intravenous cocaine use in previous clinical research. This grant will assist in the ongoing development of TNX-1300 as a treatment for life-threatening cocaine intoxication, which was responsible for more than 24,900 drug overdose fatalities in the United States in 2021.

Key Segments Profiled in the Cocaine Intoxication Treatment Industry Survey

Drug Class:

Phentolamine
Lorazepam
Diazepam
Verapamil
Morphine

Route of Administration:

Oral
Inhalation
Intravenous
Nasal

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Serum Lactate Testing Market Set to Witness Robust Growth, Expected to Reach USD 491.7 Million by 2033

The global serum lactate testing market is poised for remarkable growth, with its current valuation standing at USD 193.8 million in 2023. Over the next decade, the market is projected to grow at an impressive CAGR of 8.9%, reaching an estimated worth of USD 491.7 million by 2033.

Serum lactate testing plays a pivotal role in diagnosing and monitoring critical conditions, including sepsis, hypoxia, and metabolic disorders. The increasing prevalence of these conditions, coupled with advancements in point-of-care diagnostic technologies, is driving the demand for efficient serum lactate testing solutions globally.

Key Growth Drivers:

Rising Incidence of Critical Illnesses: The growing global burden of sepsis and related complications has heightened the demand for serum lactate tests as a standard diagnostic tool.
Technological Advancements: Innovations in diagnostic devices, such as portable and automated analyzers, are enabling faster and more accurate test results, boosting market adoption.
Increased Awareness and Preventive Healthcare Practices: Growing awareness among healthcare providers and patients about the benefits of early diagnosis is fueling market expansion.

Market Outlook:

The forecasted growth reflects a significant shift in healthcare priorities, with increasing investments in diagnostics to improve patient outcomes. Emerging markets, particularly in Asia-Pacific and Latin America, are expected to offer lucrative opportunities due to their expanding healthcare infrastructure and rising healthcare expenditure.

As the healthcare industry continues to prioritize early and accurate diagnostics, the global serum lactate testing market is set to play a critical role in enhancing patient care outcomes. Market players are encouraged to focus on innovation, strategic collaborations, and market expansion to tap into the growing demand.

Key Takeaways:

The market is predicted to be widespread at a phenomenal pace due to a surge in athletics and sports activities, creating a huge opportunity for market players to step into the market.
As a matter of fact, athletes and sportspersons require to check their lactate levels throughout the training process or a race because at that time the lactate flows to various parts of the body, including the bloodstream.
Serum lactate testing shows accurate levels of lactate, as it is in an equilibrium state in the body. The rise in sports activities and participation of individuals in these activities increases the number of participants who would need to test their lactate levels, as a surge in the level of lactate in the blood could lead to adverse effects in the body.
Appropriate lactate measures are considered markers for accessing the conditioning of the energy systems which aid in predicting the race performance. Hence, a trainer needs to test and measure the lactate levels of a performer.
A significant surge in athletic and sports activities drives the need and usage of lactate meters in order to test lactate levels before and during the performance. Hence, an increase in sports activities presents lucrative opportunities in the market during the assessment period.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

Competitive Landscape:

Prominent companies in the serum lactate testing market are focusing on adopting key differentiating strategies such as increasing product pipelines and regulatory approvals, expanding into other regions, and brand management approvals in different regions. Because of increased awareness, the market’s dynamics have shifted.

Recent Development:

In March 2021, Roche finalized a merger agreement with GenMark Diagnostics, Inc., aiming to leverage innovative technologies that enable testing for multiple infections using a single patient sample.
In June 2021, Nova Biomedical introduced the Stat Profile Prime Plus blood gas analyzer, featuring a new critical care parameter designed to rapidly calculate and report mean corpuscular hemoglobin concentration.
In July 2021, Liverpool FC partnered with EFK Diagnostics through a contract for lactate kits.

Key Companies Profiled:

F. Hoffmann-La Roche AG
Nova Biomedical
COSMED srl
ApexBio
Arkray, Inc.
EFK Diagnostics
Sensa Core Medical Instrumentation Pvt. Ltd.
TaiDoc Technology
BST Biosensor Technology
Analox Instruments Limited
Marshal Scientific LLC

Key Market Segments Covered in the Serum Lactate Testing Industry Research

Product:

Table Top Analyzers
Hand-Held Meters
Test Strips

Application:

Medical Intervention
- Hypoxia
- Obstetrics
- Post Surgery Infection
- Other
Sports Application
Veterinary Application

End User:

Hospitals
Diagnostic Laboratories
Sports Institutes
Specialty Clinics
Home Care Settings

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)

About Future Market Insights (FMI)

Contact Us:

Global Instrument Detergents for Manual Cleaning Market to be valued at USD 653.7 Million by 2033 Due to Rising Necessity for Reusable Medical Equipment | FMI

The global instrument detergents for manual cleaning market are projected to create a healthy CAGR of 3.9% from 2023 to 2033. The global market was valued at around USD 653.7 Million in 2033 reaching up from USD 428.3 Million in 2022. According to a recent study by Future Market Insights, enzymatic detergents are leading the market with a share of about 70.6% in the year 2022, within the global market.

The global demand for instrument detergents for manual cleanings is on the surge attributed to the propelling rates of surgeries and awareness in the prevention of infectious diseases. The demand for the market will expand over the forecast period because of the rising awareness of the hazardous hospital-acquired disease and the necessity for reusable medical equipment and devices. Owing to the stringent cleanliness regulations and higher standards for hygiene, the demand for detergent has been gradually rising in recent years and is anticipated to continue growing throughout the forecast period.

The market value for instrument detergents for manual cleaning was approximately 18.6% within the overall USD 2.3 Billion of the global medical device cleaning market in 2022. Within hospitals, a variety of medical devices are used while operating on patients or performing surgeries. Before and after each use, this medical equipment needs to be sanitized and cleaned. Most manufacturers understand the advantages of instrument detergents, which is driving them to focus more on the development of enzymatic formulations of detergents to meet the increasing demand for instrument detergents in the global market.

Key Takeaways:

At the global level, the rising number of surgeries and endoscopic procedures are the primary driving factors for the global market. Furthermore, changes in the lifestyles of consumers all over the region are leading to a rise in the number of lifestyle-associated diseases such as cancer and heart ailments. An increase in the prevalence of such diseases has led to a rise in the number of surgeries.
A surge in the geriatric population has resulted in a high number of surgeries comprising knee replacement and cataract operations, among others. Furthermore, the augmentation in the number of surgeries is expected to have a positive impact on the market.
As the number of surgeries increases, the demand for cleaning processes will also increase. For example, as per “Dobson GP. Trauma of major surgery: A global problem that is not going away. Int J Surg. 2020”, 310 million major surgeries are carried out every year throughout the entire world.
Manufacturers concentrate on the production of enzymatic detergents. Healthcare benefits and significant cost savings result from investing more money in multi-enzymatic detergents that are effectively formulated and validated, which create enzymatic detergents in the instrument detergent category, the top choice for most end users.
Due to all these positive factors, the demand for instrument detergents is rising exponentially. Due to all these positive factors, the demand for instrument detergents is rising exponentially.

Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!

Competitive Landscape:

The global market for instrument detergents for manual cleaning is consolidated, with a few established competitors. These businesses are employing strategies including mergers and acquisitions, partnerships, collaborations, and new product launches to satisfy consumer demand and increase their client base. Regional governments take initiative to invest in instrument detergents for manual cleaning equipment.

More Insights into the Global Instrument Detergents for Manual Cleaning Market

The North American market is anticipated to dominate the global instrument detergents for manual cleaning market. The U.S.A. accounted for around 94.2% of the total market share in 2022 and is expected to continue to experience the same growth throughout the forecast period. In the USA the market is expanding as the population of older people is increasing rapidly.

Japan is another market that exhibited lucrative growth of around 44.5% in 2022, with a market value of USD 27.1 Million in the East Asia instrument detergents for manual cleaning market 2022.

Top manufacturers in Japan supply instrument detergents at a lower cost. Local players manufacture instrument detergents at high volumes as compared to other global players.

Domestic key players that specialize in instrument detergents for manual cleaning are growing significantly to meet the expected rise in demand for instrument detergents. Manufacturers supply instrument detergents to local hospitals and ambulatory surgical centers at lower costs, and this factor will boost the market expansion in Japan. Therefore, demand within the market is rapidly increasing in Japan.

Key Companies Profiled:

STERIS Plc
Ecolab
Getinge Group
Serchem Ltd.
Ruhof
Medline
Advanced Sterilization Products
Schülke & Mayr GmbH
Medalkan
Metrex Research
Dr. Weigert
Boston Scientific Corporation
Enzyme Solutions Incorporated
Falconfire Inc.
BeliMed
Crosstex International, Inc.
Amity International

Key Market Segments Covered in Instrument Detergents for Manual Cleaning Industry Research:

By Detergent:

Enzymatic Detergents
Neutral Detergents
Acidic Detergents
Alkaline Detergents

By Instrument:

Surgical instruments
Endoscopes

By End User:

Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Specialty Clinics
Others

About Future Market Insights (FMI)

Contact Us:

Increasing Incidence of Whim Syndrome Management Market to Propel the Growth at 6% CAGR through 2033: FMI Study

The global whim syndrome management market is currently in its infancy, but it is expected to grow significantly in the coming years. The increasing prevalence of Whim Syndrome, coupled with the growing demand for effective treatment options, is driving the growth of this market. According to a new market research report published by Future Market Insights, the global Whim syndrome management market is projected to reach a value of USD 10 million by 2023, growing at a CAGR of 6% during the forecast period, surpassing USD 17.91 Million valuation by 2033.

One of the key factors driving the growth of the Whim syndrome management market is the increasing prevalence of this rare genetic disorder. Although Whim Syndrome is a rare disorder, the incidence of this condition is increasing. According to the National Organization for Rare Disorders (NORD), the incidence of Whim Syndrome is estimated to be around 1 in every 50,000 to 100,000 people worldwide.

Another factor driving the growth of the Whim syndrome management market is the increasing demand for effective treatment options. Currently, there are no approved treatments for Whim Syndrome. However, several companies are developing potential therapies for this rare disorder, and many of these treatments are in the late stages of clinical development.

In conclusion, the Whim syndrome management market is expected to grow significantly in the coming years, driven by the increasing prevalence of this rare genetic disorder and the growing demand for effective treatment options. As more treatments become available for Whim Syndrome, the demand for these treatments is expected to increase, driving the growth of this market.

Key Takeaways from the Market Study:

From 2018 to 2022, the whim syndrome management market grew at a CAGR of 4%.
The global Whim syndrome management market is expected to grow with a 6% CAGR during 2023 to 2033.
As of 2033, the Whim syndrome management market is expected to reach USD 17.91 Million.
According to the FMI analysis, hospital pharmacies account for the largest market share.
North America is expected to possess 40% market share for the Whim syndrome management market.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Whim Syndrome Management.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Market Competition:

Key players in the market include pharmaceutical companies such as X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences along with healthcare providers and technology companies among other global players.

Under the guidance of Philip Murphy, M.D. and David McDermott, M.D., researchers from the IRP have identified and enrolled three patients with advanced WHIM syndrome, who were ineligible for standard treatment, in an open-label study. These patients were administered low doses of plerixafor, and all three experienced a reduction in infection frequency and a significant enhancement in their quality of life. The utilization of plerixafor to treat WHIM syndrome is a new approach for patients who are unable to manage their symptoms using traditional therapies. Consequently, a randomized, double-blind Phase 3 trial has been developed to compare plerixafor to standard treatment, evaluate its clinical effectiveness, and gather additional safety information. You can find this trial on ClinicalTrials.gov with the identifier NCT02231879.

Key Segments Profiled in the Whim Syndrome Management Industry Survey:

Drug Class:

Mavorixafor
Plerixafor

Route of Administration:

Oral
Parenteral
Injectable

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Register 4.9% CAGR from 2023 to 2033: FMI Study

During the forecast period 2023 to 2033, the atypical hemolytic uremic syndrome (ahus) treatment market is expected to grow at a value of 4.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Atypical hemolytic uremic syndrome (ahus) treatment is expected to rise up to a market valuation of USD 2308.84 Million. Growth of the market can be attributed to increasing prevalence of the disease, rising awareness among healthcare professionals, and the introduction of innovative therapies that offer improved efficacy and safety profiles.

The market for aHUS treatment is also benefiting from increasing awareness of the disease among healthcare professionals and patients. As more physicians become familiar with the symptoms and diagnosis of aHUS, patients are more likely to receive a timely and accurate diagnosis, which can improve their chances of a favorable outcome.

In addition, pharmaceutical companies are investing in research and development of new therapies for aHUS, which is leading to the introduction of new treatments with improved efficacy and safety profiles. This is creating a competitive landscape for aHUS treatment, with companies vying for market share through the development of innovative therapies and effective marketing strategies.

Key Takeaways from the Market Study:

The Atypical hemolytic uremic syndrome (ahus) treatment market is expected to grow at a value of 4.9% CAGR in the forecast period 2023-3033.
By distribution channel, hospitals are expected to hold 45% of the market share in 2023 for Atypical hemolytic uremic syndrome (ahus) treatment market.
North America is expected to possess 44% market share for Atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
Europe Atypical hemolytic uremic syndrome (ahus) treatment market size is expected to possess 38% market share in 2023.

“The market is also likely to benefit from the growing demand for personalized medicine, as patients with aHUS may require different treatment approaches based on their individual genetic and medical profiles.” states an FMI analyst

Enhanced Market Demand! Discover Thorough Trends and Insights in Our Complete Report!

Competitive Landscape:

Key players in the atypical hemolytic uremic syndrome (ahus) treatment market are Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Tasly Biopharmaceuticals, Prestige BioPharma, Abbott Medtronic, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc.

Omeros Corporation, a key player in the atypical hemolytic uremic syndrome (ahus) treatment market is offering narsoplimab (also known as OMS721), which is a first-in-class monoclonal antibody that targets the lectin pathway of the complement system. The lectin pathway is one of the three pathways in the complement system that can become overactivated in patients with aHUS.
Novartis has been involved in research into other potential treatments for aHUS. One of the most promising of these is iptacopan (LNP023), a first-in-class oral inhibitor of the complement system.

Key Segments Profiled in the Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Industry Survey:

Product Type:

Mono
Combination
Mono/Combination

Molecule Type:

Monoclonal Antibody
Peptides

Polymer:

Small molecule
Gene therapy

Route of Administration:

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

About Future Market Insights (FMI)

Contact Us:

Growing Preference for Discrete Analyzers over Flow Analyzers Is Uplifting the Discrete Analyzers Market to reach a valuation of ~USD 2.6 Billion by the year 2033: Future Market Insights

According to Future Market Insights’ latest industry analysis, the market size for the global discrete analyzers market is expected to reach USD 1.5 Billion in 2023. It is projected to exhibit growth at a CAGR of 5.2% over the forecast period, with an estimated market size of ~USD 2.6 Billion by 2033.

High levels of air pollution and nutrient discharges from agriculture and wastewater continue to harm ecosystems, reduce agricultural production, and cause eutrophication and acidification. It is anticipated that pollution will significantly rise over the ensuing decades that directly affects human health and has an impact on ecosystems, soil, water, and air. Thus, increasing pollution will grow the demand for discrete analyzers in the market.

Cross-contamination and detection issues caused by frequent washing and reuse of cuvettes or by cleaning the liquid channel inside a flowcell are eliminated when using disposable cuvettes. This advantage of discrete analyzers results in the high usage of discrete analyzers.

The government’s goal is to broaden the scope of pollution monitoring, not to replace or displace current laboratories. The discrete analyzer technique will contribute to expanding the reach of environmental laboratories.

Companies involved in the global discrete analyzers market are actively working to improve their competitiveness through new product introductions, business expansion, regulatory clearances, partnerships, and agreements with both established and emerging competitors.

Acquisitions and mergers significantly accelerate a manufacturer’s ability to capture a significant share of the market. Some of the recent instances of this trend are:

Key Takeaways from Market Study

Discrete analyzers system held a 6% market share in the product segment of the global discrete analyzers market in 2022, owing to excellent product quality and accuracy.
Bench top discrete analyzers accounted for 4% of the global market share in the modality segment of the global discrete analyzers market in 2022. This is because these analyzers perform different tests quickly on a variety of samples.
Environmental testing labs segment held a share of 3% of the end-user category of the global discrete analyzers market in 2022, due to the serious global contamination incidents.
North America held a market share of 4% in 2022, owed to the high prevalence of waterborne diseases.

“Increasing Prevalence of Water Borne Diseases and the Advancements in Terms of Technology used in Water Quality Monitoring is set to Propel Sales of the Discrete Analyzers Market across the Globe,” says an analyst of Future Market Insights.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Market Competition:

The discrete analyzers market is highly fragmented because of the large number of players in the market both local and international. There is a broad range of products that can be categorized under the discrete analyzers market, making it a broad market. The strategies that are majorly followed by the key players of the discrete analyzers market include product launches and expansions.

In August 2022, Abbott Laboratories, a major U.S. provider of medical technology, is investing 440 million euros in Ireland to create new jobs in Donegal and a sizable new manufacturing facility in Kilkenny.
In Jan 2020, the suPARnostic® TurbiLatex product from ViroGates received regulatory approval (CE-IVD) for use with Siemens Healthineers’ ADVIA® Chemistry XPT System. The suPARnostic® TurbiLatex solution from ViroGates is now available for clinical regular usage in hospitals using ADVIA XPT systems.

Key Companies Profiled:

Thermofisher Scientific Inc.
Seal Analytical
Skalar Analytical B.V.
Chinchilla Scientific
SYSTEA S.p.a
Astoria-Pacific, Inc.
Siemens Industry, Inc.
NECi Superior Enzymes
Abbott Laboratories
Roche Holding AG
KPM Analytics

Key Market Segments Covered in Discrete Analyzers Industry Research:

Product:

Discrete Analyzer System
- <140 Tests Capacity
- 150-200 Tests Capacity
- 201-450 Tests Capacity
- 451-600 and more Tests Capacity
Consumables
- Cuvettes
- Reagents
- Coils
Software

Modality:

Standalone discrete Analyzers
Bench Top Discrete Analyzers

End User:

Waste Water Plants
General Testing Labs
Environmental Testing Labs
Agriculture and Food Testing Labs
Pharmaceutical Companies
Government and Academic Institutes and Laboratories
Contract Research Organization

Region:

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa

About Future Market Insights (FMI)

Contact Us: